Clinical trialNCT07339384Not, yet, recruitingInterventional

Signatera Assessment in Early-Stage Endometrial Cancer

SponsorNatera, Inc.Enrollment1,010Endometrial Cancer

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The goal of this clinical trial is to assess if circulating tumor DNA can guide adjuvant selection in high-intermediate risk early-stage endometrial cancer. The main question it aims to answer is: • To evaluate if 3-year recurrence-free survival among women with Stage I, high-intermediate risk endometrial cancer who are ctDNA negative after receiving ctDNA-guided observation is non-inferior to adjuvant vaginal brachytherapy (an internal radiation therapy) Researchers will compare high-risk intermediate ctDNA negative participants who are observed to those who receive vaginal brachytherapy to see if they have similar outcomes. Participants will be asked to: * Receive serial ctDNA testing * Visit their study doctor per their standard of care visits about every 3 months for 2 years * Answer a questionnaire about their well-being

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Adam ElNaggar, MD
Natera, Inc.
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

12 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

University of Alabama at Birmingham Hospital
Birmingham, Alabama, United States
Michael Toboni, MD
University of California, San Diego
La Jolla, California, United States
Ramez Eskander, MD
University of California, Los Angeles
Los Angeles, California, United States
Dana Chase, MD
University of Miami
Miami, Florida, United States
Abdulrahman Sinno, MD
University of Chicago
Chicago, Illinois, United States
Katherine Kurnit, MD
University of Minnesota
Minneapolis, Minnesota, United States
Melissa Geller, MD
New York University
New York, New York, United States
Bhavana Pothuri, MD
Atrium Health Levine Cancer
Charlotte, North Carolina, United States
Allison Puechl, MD
Duke University
Durham, North Carolina, United States
Angeles Secord, MD
Cleveland Clinic
Cleveland, Ohio, United States
Kevin Elias, MD
Ohio State University Wexner Medical Center
Columbus, Ohio, United States
Floor Backes, MD
Allegheny Health
Pittsburgh, Pennsylvania, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study. It may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 Oct 2026
Primary completion: 31 Oct 2034
Completion: 31 Oct 2034
Last update posted: 17 Jun 2026
Registered enrollment: 1,010
Registry id: NCT07339384

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.